Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04157049 · ClinicalTrials.gov registry record
Alpha-1 Research Registry
A clinical trial of Alpha-1 Antitrypsin Deficiency, sponsored by Alpha-1 Foundation.
- Recruiting
- Registry status
- 4,000
- Enrollment target
- 1
- Study location
NCT04157049 is a study of Alpha-1 Antitrypsin Deficiency that is actively recruiting participants, run by Alpha-1 Foundation. The registered enrollment target is 4,000 participants, above the 2,856-participant average among 18 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (40% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04157049, a study of Alpha-1 Antitrypsin Deficiency, is actively recruiting participants, sponsored by Alpha-1 Foundation.
- RECRUITING
- Registry status
- 4,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The Alpha-1 Research Registry is a confidential database made up of individuals diagnosed with Alpha-1 Antitrypsin Deficiency (Alpha-1) and individuals identified as Alpha-1 carriers. The Registry was established to facilitate research initiatives and promote the development of improved treatments and a cure for Alpha-1.
Conditions Studied
Study Locations (1)
Florida
- Alpha-1 Foundation - Coral Gables
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2019-06-20 |
| Est. Completion | 2029-06-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04157049
The ClinicalTrials.gov registry entry for NCT04157049 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,856-participant average among 18 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (40% higher). The listed sponsor is Alpha-1 Foundation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 0 interventions.
NCT04157049 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04157049 about?
NCT04157049 is a clinical study titled "Alpha-1 Research Registry". The Alpha-1 Research Registry is a confidential database made up of individuals diagnosed with Alpha-1 Antitrypsin Deficiency (Alpha-1) and individuals identified as Alpha-1 carriers. The Registry was established to facilitate research initiatives and promote the development of improved treatments a...
What is the current status of trial NCT04157049?
This trial is currently recruiting. The enrollment target is 4,000 participants. The study started on 2019-06-20. Estimated completion is 2029-06-20.
What conditions does trial NCT04157049 study?
This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency.
Who is sponsoring clinical trial NCT04157049?
This trial is sponsored by Alpha-1 Foundation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04157049 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha-1 Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
RECRUITING
-
PiMZ Longitudinal Cohort (PiMZ Logic)
RECRUITING
-
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
RECRUITING · Phase 2
-
Gene Therapy for Alpha 1- Antitrypsin Deficiency
RECRUITING · Phase 1
-
A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.